No, empagliflozin does not precipitate diabetes—it prevents and treats it.
Empagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes, not cause it. In fact, the evidence demonstrates that empagliflozin actually reduces the risk of developing diabetes in people with prediabetes.
Empagliflozin Prevents Diabetes Development
A 2022 meta-analysis of randomized controlled trials found that SGLT2 inhibitors, including empagliflozin, were associated with a 21% reduction in the risk of new-onset type 2 diabetes among adults with prediabetes (relative risk 0.79,95% CI 0.68-0.93) 1. Specifically for empagliflozin, the relative risk was 0.87 (95% CI 0.72-1.04), indicating a protective trend 1.
Mechanism of Action: Glucose Lowering, Not Glucose Raising
Empagliflozin works by blocking glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine 2. This mechanism:
- Lowers blood glucose levels by eliminating 60-100 grams of glucose daily 3
- Reduces HbA1c by 0.5-0.8% when added to existing diabetes therapy 4, 5
- Improves insulin sensitivity and reduces insulin resistance 6
- Promotes weight loss of 1.8-3.4 kg, which further improves metabolic health 7
FDA-Approved Indications
According to the FDA drug label, empagliflozin is indicated for 8:
- Improving glycemic control in adults with type 2 diabetes
- Reducing cardiovascular death risk in adults with type 2 diabetes and cardiovascular disease
- Treating heart failure (with or without diabetes)
The drug is contraindicated in type 1 diabetes 9, 10, not because it causes diabetes, but because it can increase ketoacidosis risk in insulin-deficient states.
Clinical Evidence Across Multiple Populations
Major cardiovascular outcomes trials consistently demonstrate empagliflozin's glucose-lowering efficacy 11, 12, 13:
- EMPA-REG OUTCOME: Reduced HbA1c by 0.3-0.36% versus placebo in established diabetes 13
- EMPEROR-Reduced/Preserved: Demonstrated benefits in heart failure patients, approximately 50% of whom had diabetes 9, 14
- Studies in youth: Empagliflozin reduced HbA1c by 0.84% in adolescents with type 2 diabetes 15
Important Safety Considerations
While empagliflozin does not cause diabetes, clinicians should be aware of:
- Euglycemic ketoacidosis: Rare but serious risk, particularly in insulin-deficient states or during illness/fasting 8, 16, 7. Discontinue 3-4 days before surgery 2.
- Genital mycotic infections: Occur in 10-15% of women and uncircumcised men 9, 8
- Volume depletion: Monitor in elderly, those on diuretics, or with renal impairment 11, 8
- Initial eGFR decrease: Transient 5 mL/min drop that stabilizes and ultimately slows long-term kidney function decline 3
Bottom Line
Empagliflozin treats diabetes and prevents its development in high-risk individuals—it absolutely does not precipitate or cause diabetes. The confusion may arise from the rare occurrence of euglycemic ketoacidosis, which is a complication of treatment in susceptible patients, not the development of new diabetes. Current guidelines strongly recommend empagliflozin for patients with type 2 diabetes and cardiovascular disease, heart failure, or chronic kidney disease 9, 10, 12, 2, 14.